Radiolabeling and biodistribution of new acetylcholinesterase inhibitor - 6-Hydrazino-IV-[5-(2,3-dihydro-1H-cyclopenta[b] quinolin-9-ylamino)pentyl] nicotinamide hydrochloride
Abstrakt
Nowadays research concerning new strategies for earlier diagnosis is among the most active areas in Alzheimer's science. Brain imaging techniques are among the most promising areas of research focused on early detection of Alzheimer’s disease (AD).
In the present study we describe radiolabeling of a novel acetylcholinesterase inhibitor 6-hydrazino-N-[5-(2,3-dihydro-1H-cyclopenta[b]quinolin-9-ylamino)pentyl]nicotinamide (5C-5) with 99m-Technetium (99mTc). Biodistribution study of compound 5C-5 radiolabeled with 99mTc after intravenous administration to rats was also performed.
According to biodistribution study 99mTc-radioactivity was mainly localized in the liver, partly also in the kidney, lung and gastrointestinal tract. Furthermore, compound under study revealed comparatively rapid blood radioactivity clearance.